Leonid Timashev
Stock Analyst at RBC Capital
(2.80)
# 1,922
Out of 4,761 analysts
64
Total ratings
38.98%
Success rate
0.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Outperform | $143 → $192 | $137.75 | +39.38% | 8 | Feb 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Reiterates: Outperform | $40 | $18.57 | +115.40% | 6 | Jan 24, 2025 | |
| INCY Incyte | Reiterates: Sector Perform | $70 | $72.11 | -2.93% | 1 | Jan 23, 2025 | |
| CMPS COMPASS Pathways | Reiterates: Outperform | $18 | $4.21 | +327.55% | 4 | Jan 15, 2025 | |
| PYXS Pyxis Oncology | Reiterates: Outperform | $10 → $8 | $1.28 | +525.00% | 5 | Dec 20, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $80 → $82 | $50.26 | +63.15% | 2 | Dec 18, 2024 | |
| LEGN Legend Biotech | Reiterates: Outperform | $86 | $39.70 | +116.62% | 12 | Dec 9, 2024 | |
| BHVN Biohaven | Reiterates: Outperform | $58 → $61 | $36.91 | +65.27% | 9 | Dec 4, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $32 → $42 | $27.07 | +55.15% | 9 | Sep 20, 2024 | |
| DSGN Design Therapeutics | Reiterates: Sector Perform | $4 | $4.91 | -18.53% | 8 | Aug 6, 2024 |
Axsome Therapeutics
Feb 19, 2025
Maintains: Outperform
Price Target: $143 → $192
Current: $137.75
Upside: +39.38%
NewAmsterdam Pharma Company
Jan 24, 2025
Reiterates: Outperform
Price Target: $40
Current: $18.57
Upside: +115.40%
Incyte
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $72.11
Upside: -2.93%
COMPASS Pathways
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $4.21
Upside: +327.55%
Pyxis Oncology
Dec 20, 2024
Reiterates: Outperform
Price Target: $10 → $8
Current: $1.28
Upside: +525.00%
Cytokinetics
Dec 18, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $50.26
Upside: +63.15%
Legend Biotech
Dec 9, 2024
Reiterates: Outperform
Price Target: $86
Current: $39.70
Upside: +116.62%
Biohaven
Dec 4, 2024
Reiterates: Outperform
Price Target: $58 → $61
Current: $36.91
Upside: +65.27%
Edgewise Therapeutics
Sep 20, 2024
Maintains: Outperform
Price Target: $32 → $42
Current: $27.07
Upside: +55.15%
Design Therapeutics
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $4.91
Upside: -18.53%